Multicenter, Open-Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meni...
Multicenter, Open-Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy
About this item
Full title
Author / Creator
Publisher
Oxford: The University of Chicago Press
Journal title
Language
English
Formats
Publication information
Publisher
Oxford: The University of Chicago Press
Subjects
More information
Scope and Contents
Contents
Background. In the absence of an efficacious broadly protective vaccine, serogroup B Neisseria meningitidis (MenB) is the leading cause of bacterial meningitis and septicemia in many industrialized countries. An investigational recombinant vaccine that contains 3 central proteins; Neisserial adhesin A (NadA), factor H binding protein (fHBP) and Nei...
Alternative Titles
Full title
Multicenter, Open-Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_759878393
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_759878393
Other Identifiers
ISSN
1058-4838
E-ISSN
1537-6591
DOI
10.1086/656741
